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Background/aim: Two different scoring systems were developed to determine the severity of bronchiectasis: FACED scoring and the
bronchiectasis severity index (BSI). In this study, we aim to compare these 2 scoring systems according to the 6-min walking distance
test and a disease-specific health status questionnaire in patients with noncystic fibrosis bronchiectasis (NCFB).
Materials and methods: Smoking history, emergency and hospital admissions, and body mass index were obtained from NCFB patients
admitted to our hospitals’ pulmonary rehabilitation unit between 2013 and 2018. Detailed pulmonary function tests were performed
for all participants. Dyspnea perceptions were determined according to the mMRC dyspnea scale. The 6-min walking test was used to
determine exercise capacity. The Saint George respiratory questionnaire (SGRQ) was applied to determine health status. Both FACED
and BSI scores were calculated for all participants.
Results: There were a total of 183 participants, 153 of whom were men. A significant and strong correlation was found between
FACED and BSI scores. As the severity of bronchiectasis increased, walking distance was significantly decreased and health status
was significantly worse in both FACED and BSI scoring. A statistically significant but weak negative correlation was found between
FACED score and walking distance. There was a significant negative correlation between BSI and walking distance, a stronger negative
correlation than with FACED. Similarly, there was a significant negative correlation between health status and both FACED and BSI, but
this correlation was stronger in the BSI score.
Conclusion: Although both FACED and BSI scores were negatively correlated with walking distance and health status in patients with
NCFB, BSI was more strongly associated.
Key words: Noncystic fibrosis bronchiectasis, FACED score, BSI score, 6-min walking distance, health status

1. Introduction
Bronchiectasis, which is now termed muco-obstructive lung
disease, is actually an orphan disease [1]. Bronchiectasis is a
clinical-radiological diagnosis characterized by irreversible
airway dilatation with chronic inflammation, which has the
clinical features of cough, sputum production, and episodic
exacerbations [2].
Bronchiectasis is classified into 2 categories, noncystic
fibrosis bronchiectasis (NCFB) and cystic fibrosis
bronchiectasis (CFB). NCFB has gained attention with
increasing awareness. With the increased use of highresolution CT scan, more patients have received a diagnosis
of bronchiectasis. The severity and the prognosis of NCFB
cannot be determined by only one parameter. Therefore,
there are several validated scores in determining the
severity and prognosis of this disease. Two of these are the
FACED score and the bronchiectasis severity index (BSI)

[3,4]. The FACED score is a 5-point score that predicts
probability of all-cause mortality. The FACED score consists
of forced expiratory volume in 1 sec (FEV1) % predicted,
age, chronic colonization by Pseudomonas aeruginosa,
extension of the disease by radiological assessment, and
dyspnea [3]. However, BSI score is a 7-point score that
determines risk for future mortality and hospitalizations
for NCFB patients [4]. In addition to the criteria of the
FACED score, the number of emergency visits and number
of hospitalizations are also calculated in the BSI score.
Unfortunately, there are no studies comparing the 2
scores in association with exercise capacity and health
status in patients with NCFB. Therefore, in the present
study we aimed to compare the results of the assessment
of 6-min walking distance and health status (SGRQ)
parameters in the same patients with NCFB assessed with
both the FACED score and the BSI.
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2. Materials and methods
We conducted a retrospective database study in our Chest
Diseases and Surgery Education and Training Hospital
between 2013 and 2018 to compare the results of the
assessment of 6-min walking distance and health status
parameters in patients with NCFB assessed with both the
FACED score and the BSI. The study was approved by the
local institutional review board. Patients included in the
study completed an informed written consent form.
2.1. Subject selection
All patients with NCFB were referred to our Pulmonary
Rehabilitation Unit for the PR program. Of the 218 NCFB
patients, 183 were eligible to participate the study. The
inclusion criteria were having bronchiectasis on high
resolution computerized tomography (HRCT) of the lungs
with or without airway obstruction. The exclusion criteria
were having an interstitial lung disease pattern (to exclude
traction bronchiectasis) on HRCT, having concurrent lung
cancer, or having a history of having had a lobectomy or
pneumonectomy for lung cancer.
2.2. Measurements
Age, sex, and body mass index (BMI) as demographics
and clinical history (smoking history, colonization with
P. aeruginosa, radiologic severity according to HRCT,
emergency admission, and hospitalization in the last year)
were recorded.
2.3. Respiratory functions
Body plethysmography (ZAN 500, nSpire Health GmbH,
Oberthulba, Germany) and carbon monoxide diffusion
capacity (ZAN 300) are routinely measured for all patients
with NCFB who are admitted to our hospital PR unit
[5]. We recorded the % predicted values of FEV1, FVC,
FEV1/FVC ratio, and carbon monoxide diffusion capacity
(TLCO).
2.4. Dyspnea assessment
We used the modified Medical Research Council (mMRC)
dyspnea scale, which consists of 5 items ranging between 0
and 4, to determine the severity of the patients’ shortness
of breath. The score 0 represents the best level, while the
score 4 indicates the poorest [6].
2.5. Exercise capacity
We recorded the walking distance in the 6-min walking
test (6mWD) performed according to the American
Thoracic Society (ATS) guidelines [7].
2.6. Health status
We used the St. George’s respiratory questionnaire
(SGRQ) to determine disease-specific health status [8].
The participants’ psychological status was determined
by the hospital’s anxiety depression scale [9]. All of these
questionnaires are routinely given to all of our pulmonary
rehabilitation candidates.
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2.7. Bronchiectasis indexes
Both FACED and BSI scores were calculated for all
participants, and participants were divided into 3 groups
as mild (0–2 for FACED, 0–4 for BSI) moderate (3–5 for
FACED, 5–8 for BSI), and severe (6–7 for FACED, >9 for
BSI). All data, especially walking distance and health status
data, were compared between these 2 scoring systems. A
bronchiectasis exacerbation was defined as a patient with
bronchiectasis with deterioration for at least 48 h in ≥3
of the following symptoms: cough, sputum volume and/
or consistency, sputum purulence, breathlessness and/or
exercise intolerance, fatigue and/or malaise, hemoptysis
[10].
2.8. Statistical analysis
The Statistical Package for the Social Sciences (IBM Corp.,
Armonk, NY, USA) v. 22 was used for data analysis.
Before the statistical analysis, the parameters were tested
for normal distribution with Kolmogorov–Smirnov
and Shapiro–Wilk tests. Results are presented as mean
± standard deviation, median (minimum-maximum),
number (n), or percentage (%) according to the statistical
method. One-way ANOVA test was used for continuous
variables when comparing clinical data of patients between
the BSI and FACED groups. As the number of patients
differed between the groups and homogeneity of variance
was provided, Hochberg’s test was used for posthoc
analysis. Hochberg’s test allows for clearly unequal sample
sizes. The relationship between the BSI and FACED scores
of the patients and the relationship between the 6-min
walking distance measurement values and SGRQ health
status scores of the patients were demonstrated by simple
linear regression analysis and Pearson’s correlation test. P
values <0.05 were considered statistically significant.
3. Results
There were 183 participants, 153 of whom were men.
The mean age of the study population was 63.1 (±10.4).
The mean FEV1 % was 33.5 ± 17.6 and the mean FEV1/
FVC ratio was 56.8 ± 14.1. There were 64 (34.9%) patients
who had the diagnosis of bronchiectasis with COPD, 7
(3.8%) with a diagnosis of bronchiectasis with asthma; the
remaining were classified as isolated bronchiectasis before
referral. Nearly half of the patients (46.8%) had at least one
comorbidity and 8 (4.3%) patients had sequel tuberculosis.
The mean FACED score of the population was 3.4 ± 1.5
while the mean BSI score was 8.9 ± 4.6. The distribution
of severity according to FACED and BSI scores is shown
in Table 1. The mean 6mWD was 331.8 ± 114.6 m. The
other demographic characteristics and the QoL scores are
shown in Table 1. According to FACED bronchiectasis
classification, patients in the severe group were older and
had higher SGRQ scores and a lower 6mWD compared
to those of the patients in the mild and moderate groups;
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Table 1. Demographic data of the participants.
Age (years) (mean ± sd)

63.1 ± 10.4

BMI (kg/m ) (mean ± sd)

25.5 ± 5.4

Sex (n, %)
Male
Female

153 (83.6%)
30 (16.4%)

mMRC (mean ± sd)

3.4 ± 1.2

Smoking history (pack-years) (mean ± sd)

55.0 ± 39.2

ER admissions (median) (min-max)

2.0 (0.0–20.0)

Hospitalizations (median) (min-max)

1.0 (0–10.0)

FEV1/FVC (mean ± sd)

56.8 ± 14.1

TLCO (mean ± sd)

35.4 ± 20.5

PaO2 (mean ± sd)

71.5 ± 13.0

PaCO2 (mean ± sd)

41.8 ± 6.2

SaO2 (mean ± sd)

93.5 ± 4.9

pH (mean ± sd)

7.4 ± 0.0

FACED score (mean ± sd)

3.4 ± 1.5

FACED scoring system (n, %)
Mild
Moderate
Severe

46 (25.1%)
114 (62.3%)
23 (12.6%)

BSI scoring system (mean ± sd)

8.9 ± 4.6

BSİ scoring system (n, %)
Mild
Moderate
Severe

38 (20.8%)
57 (31.1%)
88 (48.1%)

6mWD meters (mean ± sd)

331.8 ± 114.6

SGRQ symptom (mean ± sd)

57.8 ± 21.0

SGRQ activity (mean ± sd)

70.1 ± 20.3

SGRQ impact (mean ± sd)

53.5 ± 21.6

SGRQ total (mean ± sd)

59.2 ± 19.1

2

BMI: body mass index, mMRC: modified Medical Research
Council, ER: emergency department visit, FEV1: forced
expiratory volume in one second, FVC: forced vital capacity,
TLCO: CO diffusion capacity, PaO2: partial pressure of oxygen
in arterial blood gas analysis, PaCO2: partial pressure of carbon
dioxide in arterial blood gas analysis, SaO2: saturation of oxygen
in arterial blood gas analysis, 6mWD: six-min walk distance,
SGRQ: Saint George respiratory questionnaire.

all differences were significant (for all, P < 0.01) (Table
2). HAD scores were not significantly different between
FACED severity groups (P = 0.97 for anxiety and P = 0.91 for
depression) (Table 2). According to the BSI index, patients
in the mild group were younger, had higher 6mWD, and
had lower SGRQ scores; all differences were significant (P

< 0.01 for all) (Table 3). A statistically significant but weak
negative correlation was found between FACED score
and distance values; a statistically significant negative
correlation was found between BSI and distance values,
with a stronger correlation than FACED scores (Table 4).
A 1-point increase in FACED score corresponds to a 28.4m decrease in distance measurement; a 1-point increase
in BSI score corresponds to a 13.2-m decrease in distance
measurement.
There was a statistically significant but weak
correlation between FACED score and SGRQ total, SGRQ
symptoms, activity, and impact scores, and there was
a statistically significant but weak negative correlation
between FACED score and walking distance. There was
also a statistically significant correlation between BSI and
SGRQ total SGRQ symptoms, activity, and impact scores,
and there was a statistically significant but weak negative
correlation between BSI score and walking distance. The
correlation between BSI score and SGRQ total score was
stronger than the correlation between FACED score and
SGRQ total score. A 1-point increase in FACED score
corresponds to a 4.56 points increase in SGRG total score;
a 1-point increase in the BSI score corresponds to 1.96
points increase in SGRQ total score (Table 4). There was
a statistically significant and strong correlation between
FACED and BSI scores (P < 0.001, r = 0.639). The increase
in FACED accounted for about 41% of the increase in BSI
(R2 = 0.409). When we compared the 6mWD among the
mild, moderate, and severe FACED subgroups, there was
no statistical significance between the subgroups (Table
5). However, in moderate and severe BSI subgroups, the
6mWD was significantly lower than that of the mild BSI
subgroup (P = 0.034, P = 0.003) (Table 6).
4. Discussion
In our cohort, 183 patients with NCFB were reviewed;
comparison was performed of the 2 scores in association
with exercise capacity and health status. This study showed
that as the severity of bronchiectasis increased, walking
distance significantly decreased and health status was
significantly worsened in both FACED and BSI scoring.
Furthermore, there was a significant negative correlation
between BSI and walking distance, which was a stronger
negative correlation than with FACED. Similarly, there
was a significant negative correlation between health
status and both FACED and BSI, but this correlation was
stronger in the BSI score.
In McDonnell et al.’s European bronchiectasis cohorts,
nearly 60% of the patients were female (60% in Scotland,
58% in Italy, 51% in Belgium, and 70% in Serbia) [11].
However, 83% of the patients in our cohort were male.
Our hospital is an education and training hospital which
serves many districts and generally serves severe patients.
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Table 2. Comparison of clinical characteristics and health status of patients according to FACED bronchiectasis classification.
Mild n = 46

Moderate n = 114

Severe n = 23

P value

P* value

P** value

P*** value

Age

59.1 ± 8.8

62.8 ± 10.6

73.0 ± 5.0

<0.001

0.044

<0.001

<0.001

FACED score

1.4 ± 0.6

3.6 ± 0.6

6.0 ± 0.2

<0.001

<0.001

<0.001

<0.001

BMI

27.1 ± 4.2

25.4 ± 5.8

23.6 ± 4.7

0.051

0.285

0.055

0.386

6 mWD (meters)

395.5 ± 84.5

319.2 ± 120.4

266.3 ± 76.3

<0.001

0.045

<0.001

<0.001

SGRQ symptom

47.9 ± 18.1

59.8 ± 21.1

67.4 ± 19.5

<0.001

0.033

<0.001

<0.001

SGRQ activity

57.8 ± 17.7

72.9 ± 20.2

80.9 ± 14.7

<0.001

0.027

<0.001

<0.001

SGRQ impact

46.8 ± 18.7

53.7 ± 22.2

65.6 ± 19.4

0.003

0.038

0.002

0.041

SGRQ total

50.3 ± 16.4

60.5 ± 19.1

70.6 ± 16.6

<0.001

0.005

<0.001

0.043

* Mild vs. moderate, ** mild vs. severe, ***moderate vs. severe, one-way Anova test, Hochberg’s GT2 test for posthoc multiple
comparison.
Table 3. Comparison of clinical characteristics and health status of patients according to BSI Bronchiectasis classification.
Mild n = 38

Moderate n = 57

Severe n = 88

P value

P* value

P** value

P*** value

Age

57.5 ± 10.2

63.5 ± 9.4

65.3 ± 10.3

<0.001

0.004

<0.001

0.049

BMI

26. 5± 3.9

25.6 ± 5.3

25.0 ± 6.0

0.365

0.710

0.336

0.797

BSI score

3.2 ± 0.7

6.5 ± 1.2

13.0 ± 2.9

<0.001

<0.001

<0.001

<0.001

6mWD (meters)

409.3 ± 75.8

363.8 ± 98.6

277.5 ± 111.8

<0.001

0.043

<0.001

<0.001

SGRQ symptom

46.2 ± 19.3

54.5 ± 21.3

64.9 ± 18.9

<0.001

0.029

<0.001

0.006

SGRQ activity

57.7 ± 19.7

65.1 ± 21.3

78.7 ± 15.8

<0.001

0.031

<0.001

<0.001

SGRQ impact

44.5 ± 20.5

47.9 ± 21.7

60.9 ± 19.6

<0.001

0.045

<0.001

0.001

SGRQ total

48.7 ± 18.3

54.3 ± 19.1

66.9 ± 16.1

<0.001

0.037

<0.001

<0.001

* Mild vs. moderate, ** mild vs. severe, *** moderate vs. severe, one-way Anova test, Hochberg’s GT2 test for posthoc multiple
comparison.
BSI: bronchiectasis severity index.

Additionally, all of the patients were referred to our
pulmonary rehabilitation clinic for consideration and
evaluation of a PR program. According to our country’s
economic and social status, male patients may have more
opportunity to obtain the best health care in the intercity
referral system between hospitals. Therefore, this male
predominance may be due to the patient referral system in
our hospital’s responsive region.
In this cohort, we have taken radiologically diagnosed
NCFB patients with or without airway obstruction. It is
quite hard to distinguish pure COPD, bronchiectasis, and
overlap syndrome [12,13]. Some questions still remain
unanswered in this specific group, as bronchiectasis
is frequently diagnosed radiologically in patients with
COPD, with different clinical phenotypes. However, for
distinguishing these 2 entities, an endotype approach is
suggested [14]. According to this approach, a combination
of imaging parameters, airway inflammation markers,
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and microbiology would be used to distinguish between
true COPD, bronchiectasis, and the overlap syndrome
[14]. In our hospital, we use a combination of imaging
parameters, inflammation markers, and sputum cultures
for identification of pure bronchiectasis. However, our
cohort may have patients overlapping with COPD. In this
cohort, the mean FEV1/FVC ratio was 56.8. The majority
of the patients had airway obstruction, hence some
patients may have overlap syndrome.
Machado et al. conducted a prospective cohort
analysis of 70 patients with NCFB recruited from May
2008 to August 2010 for determining prognostic factors;
they found that the mean FEV1% was 48.0 ± 14.8 [15].
In the present study, patients with NCFB had lower FEV1
levels. As we mentioned previously, our hospital is a Step 3
education and research hospital that takes referred severe
patients. Therefore, our results may not generalize all
NCFB patients in our region.
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Table 4. Correlation of the two bronchiectasis scoring systems with 6-min walking distance and health status scores: simple linear
regression analysis.
FACED scoring system
r

BSI scoring system
B

95.0% CI

P

R2

F

P*

0.139

29.19

0.000

r

B

95.0 %CI

P

R2

F

P*

–0.533

–13.23

(–16.31)–
(10.15)

0.000

0.284

71.68

0.000

Walking
distance
(meters)

–0.373 –28.41

(–38.80)–
(–18.04)

0.000

SGRQ symptom

0.274

3.84

1.87– 5.81

0.000

0.075

14.73

0.000

0.416

1.90

1.29– 2.50

0.000

0.173

37.97

0.000

SGRQ activity

0.388

5.26

3.43– 7.09

0.000

0.151

32.13

0.000

0.477

2.10

1.53– 2.67

0.000

0.227

53.19

0.000

SGRQ impact

0.305

4.39

2.41– 6.45

0.000

0.093

19.59

0.000

0.407

1.91

1.28– 2.54

0.000

0.166

35.93

0.000

SGRQ total

0.360

4.56

2.83– 6.30

0.000

0.129

26.90

0.000

0.475

1.96

1.43– 2.49

0.000

0.225

52.68

0.000

Simple linear regression analysis.
Table 5. The correlation of 6-min walk distance and QoL scores in between FACED scoring
system subgroups.
Mild

Moderate

Severe

r

P

r

P

r

P

6mWD

–0.243

0.104

–0.117

0.214

–0.068

0.759

SGRQ total score

0.065

0.669

0.226

0.016

0.005

0.981

Table 6. The correlation of 6-min walk distance and QoL scores in between BSI scoring system
subgroups.
Mild

Moderate

Severe

r

P

r

P

r

P

6mWD

0.060

0.719

–0.281

0.034

–0.311

0.003

SGRQ total score

0.138

0.409

0.237

0.076

0.371

0.000

In the European cohort, the mean BSI scores ranged
from 6 to 9.7 while the mean FACED score was between 1.5
and 2.3 [13]. In the present cohort, the mean FACED score
of the population was 3.4 ± 1.5 while the mean BSI score
was 8.9 ± 4.6. Our results are quite similar with those of the
existing literature. In McDonnell et al.’s study consisting of 7
cohorts, the cohorts were primarily classified as moderateto-severe bronchiectasis based on mean BSI scores (6.0–
9.7); however, in contrast, the majority were classified as
mild bronchiectasis according to the FACED score (mean
1.5–2.3). In our study, the majority of the patients were
moderate based on the FACED score; however, based on
the BSI scores, the majority of the patients were severe.
When we add ER visits and hospitalizations to the scoring
system, it is seen that there is a tendency for more patients
to settle in the severe group.

These 2 scoring systems were developed for obtaining
the risk of mortality; however, these scores also correlate
well with exercise capacity. In this present cohort, according
to FACED bronchiectasis classification, severe patients
had significantly lower 6mWD scores compared to mild
and moderate groups. The same was true for the BSI score:
according to the BSI index, patients in the mild group had
significantly higher 6mWD scores. Thus, we believe that
classifying the severity of the patients according to these
scoring systems may reflect the exercise capacity of NCFB
patients.
In the same European cohort study, McDonnell et al.
suggest that the BSI is superior to FACED in predicting
clinically important disease-related outcomes, including
hospital admissions, exacerbations, QoL, respiratory
symptoms, 6mWD, and lung function decline in
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bronchiectasis [11]. In this present cohort, the correlation
between BSI and SGRQ total score was stronger than for
FACED, which is similar to the European results.
However, the literature shows different results in different
etiologies. In a study conducted by Wang et al. to evaluate
the clinical characteristics and validation of bronchiectasis
severity score systems for posttuberculosis bronchiectasis,
the authors found that both FACED and BSI can predict
mortality in posttuberculosis bronchiectasis [16]. These data
confirm that both scoring systems are excellent predictors
of medium-term mortality in subjects with bronchiectasis;
however, in a single center retrospective cohort study by
Ellis et al., both scores were able to predict 15-year mortality,
with the FACED score showing slightly superior predictive
power (AUC 0.82 versus 0.69, P = 0.0495) [17]. Although
BSI is more closely correlated with health status and exercise
capacity in the present study, FACED may be better than BSI
in some aspects, among them being the simplicity of its use
and its clinical applicability, as shown in the literature [17].
When dealing with bronchiectasis in our daily clinical
practice, it is sometimes difficult to decide which score is the
best for the individual patient [18]. With our results, we may
say that both scoring systems predicted the exercise capacity
and health status correctly in NCFB patients. However, if we
would like to make a comprehensive and detailed exercise

program for NCFB patients, we would prefer to use the BSI
score because of its stronger relation with 6mWD and health
status scores.
One of the limitations of our study is its retrospective
design. However, we have used a detailed data recording
system in order to eliminate this limitation. Additionally,
NCFB patients referred to our PR unit were symptomatic
patients with airflow limitation in need of pulmonary
rehabilitation; therefore, our findings may not be generalized
to all NCFB patients.
4.1. Conclusion
This study showed that as the severity of bronchiectasis
increased, walking distance significantly decreased and
health status significantly worsened, which was reflected
in both FACED and BSI scoring. However, the relationship
between 6mWD and health status scores was stronger in the
BSI scoring system compared to the FACED bronchiectasis
severity score.
Statement of ethics
The study was approved by the local institutional review
board in January 2017.
Conflict of interest
The authors have no conflicts of interest to declare.

References
1.

Boucher RC. Muco-obstructive lung diseases. The New
England Journal of Medicine 2019; 380 (20): 1941-1953. doi:
10.1056/NEJMra1813799

2.

King P, Holdsworth S, Freezer N, Holmes P. Bronchiectasis.
Internal Medicine Journal 2006; 36 (11): 729-737. doi:
10.1111/j.1445-5994.2006.01219.x

3.

Martínez-García MÁ, De Gracia J, Vendrell Relat M, Girón
RM, Máiz Carro L et al. Multidimensional approach to
non-cystic fibrosis bronchiectasis: the FACED score.
European Respiratory Journal 2014; 43 (5): 1357-1367. doi:
10.1183/09031936.00026313

4.

Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni
S et al. The Bronchiectasis Severity Index: an international
derivation and validation study. American Journal of
Respiratory and Critical Care Medicine 2014; 189 (5): 576585. doi: 10.1164/rccm.201309-1575OC

5.

Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F
et al. ATS/ERS task force. General considerations for lung
function testing. European Respiratory Journal 2005; 26 (1):
153-161. doi: 10.1183/09031936.05.00034505

6.

Bausewein C, Farquhar, M, Booth S, Gysels M, Higginson
IJ. Measurement of breathlessness in advanced idsease: a
systematic review. Respiratory Medicine 2007; 101 (3): 399410. doi: 10.1016/j.rmed.2006.07.003

636

7.

ATS Committee on Proficiency Standards for Clinical
Pulmonary Function Laboratories. ATS statement: guidelines
for the six-minute walk test. American Journal of Respiratory
and Critical Care Medicine 2002; 166 (1): 111-117. doi: 10.1164/
ajrccm.166.1.at1102

8.

Polatlı M, Yorgancıoğlu A, Aydemir Ö, Yılmaz Demirci N, Kırkıl
G et al. Validity and reliability of Turkish version of St. George’s
respiratory questionnaire. Tüberküloz ve Toraks 2013; 61 (2):
81-87. doi: 10.5578/tt.5404 (Turkish with an abstract in English)

9.

Zigmond AS, Snaith RP. The hospital anxiety and depression
scale. Acta Psychiatrica Scandinavica 1983; 67: 361-70. doi:
10.1111/j.1600-0447.1983.tb09716.x

10.

Polverino E, Gemine PC, McDonnell MJ, Aliberti S, Marshall
SE et al. European Respiratory Society guidelines for the
management of adult bronchiectasis. European Respiratory
Journal 2017; 50 (3): 1700629. doi: 10.1183/13993003.006292017

11.

McDonnell MJ, Aliberti S, Goeminne PC, Dimakou K, Zucchetti
SC et al. Multidimensional severity assessment in bronchiectasis:
an analysis of seven European cohorts. Thorax 2016; 71 (2):
1110-1118. doi: 10.1136/thoraxjnl-2016-208481

12.

Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC et
al. Clinical phenotypes in adult patients with bronchiectasis.
European Respiratory Journal 2016; 47: 1113-1122. doi:
10.1183/13993003.01899-2015

VAROL et al. / Turk J Med Sci
13.

Hurst JR, Elborn JS, De Soyza A. COPD-bronchiectasis overlap
syndrome. European Respiratory Journal 2015; 45 (2): 310313. doi: 10.1183/09031936.00170014

14.

Chalmers JD. Bronchiectasis and COPD overlap: a case
of mistaken identity? Chest 2017; 151 (6): 1204-1206. doi:
10.1016/j.chest.2016.12.027

15.

Machado BC, Jacques PS, Penteado LP, Roth Dalcin PT.
Prognostic factors in adult patients with non-cystic Fibrosis
Bronchiectasis. Lung 2018; 196 (6): 691-697. doi: 10.1007/
s00408-018-0165-z

16.

Wang H, Ji XB, Li CW, Lu HW, Mao B et al. Clinical
characteristics and validation of bronchiectasis severity score
systems for post-tuberculosis bronchiectasis. The Clinical
Respiratory Journal 2018; 12 (8): 2346-2353. doi: 10.1111/
crj.12911

17.

Ellis HC, Cowman S, Fernandes M, Wilson R, Loebinger MR.
Predicting mortality in bronchiectasis using bronchiectasis
severity index and FACED scores: a 19-year cohort study.
European Respiratory Journal 2016; 47 (2): 482-489. doi:
10.1183/13993003.01312-2015

18.

Guan W, Chen R, Zhong N. The bronchiectasis severity index
and FACED score for bronchiectasis. European Respiratory
Journal 2016; 47 (2), 382-384. doi: 10.1183/13993003.017172015

637

